Rodeo Therapeutics

Seattle

Facts

HQ
Seattle
Sectors
Biotech, Regenerative medicine, Pharmaceuticals
Stage
startup
Members see funding amounts.
.

Is this your organization? Claim it

Amgen to buy Seattle startup Rodeo Therapeutics for $55M upfront, up to $666M more in milestones

Amgen agreed to acquire Seattle biotech Rodeo Therapeutics, which develops small-molecule therapies to repair and regrow tissues, for $55 million upfront plus up to $666 million in contingent payments. Rodeo, led by CEO Thong Le and founded by Sanford Markowitz, Stanton Gerson and Joseph Ready, has backing from investors including AbbVie, Lilly, Arch Venture Partners and Johnson & Johnson and had raised over $14 million.

Seattle’s Rodeo Therapeutics raises $4.3M more for regenerative therapies, joining prior $3.7M infusion

Rodeo Therapeutics, a Seattle regenerative medicine startup co-founded by Drs. Sanford Markowitz, Stanton Gerson, and Joseph Ready, has added $4.3 million to an earlier $3.7 million cash infusion, building on a $5.9 million Series A from 2017. The company is developing therapies for inflammatory bowel disease and treatments to accelerate cell growth after stem cell transplants, with investors including AbbVie, Lilly, Arch Venture Partners and Johnson & Johnson.

See all 5 stories, episodes and videos about Rodeo Therapeutics.